New-onset refractory status epilepticus (NORSE) is characterized by new-onset refractory seizures in patients without prior epilepsy or clear acute structural, toxic, or metabolic causes, often necessitating early aggressive immunotherapy alongside continuous anesthetic infusions to reduce morbidity and mortality.